SlideShare ist ein Scribd-Unternehmen logo
1 von 55
Drugs That Affect the Circulatory System
Learning Objectives ,[object Object],[object Object],[object Object],[object Object]
Components and Function of the Circulatory System ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Normal Blood Circulation ,[object Object],[object Object],[object Object],[object Object],[object Object]
Components and Function of the Circulatory System
Drugs That Affect the Heart ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Uses for Cardiac Drugs ,[object Object],[object Object],[object Object],[object Object]
Heart Failure ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Drugs That Affect the Heart ,[object Object],[object Object],[object Object],[object Object],[object Object]
Diuretic Agents ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Inotropic Drugs ,[object Object],[object Object],[object Object]
Inotropic Drugs ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
ACE Inhibitors ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
ACE Inhibitors ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Beta-Blocking Agents ,[object Object],[object Object],[object Object],[object Object]
Beta-Blocking Agents ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Angiotensin II Receptor–Blocking Agents ,[object Object],[object Object],[object Object]
Angiotensin II Receptor–Blocking Agents ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Aldosterone Inhibitor Agents ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Cardiac Arrhythmias ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Drug Used to Treat Arrhythmias ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Drug Used to Treat Arrhythmias ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object]
Learning Objectives ,[object Object],[object Object],[object Object],[object Object]
Vasoconstricting Agents  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Vasoconstricting Agents ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Vasodilating Agents  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Antihypertensive Agents  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Treatment of Hypertension ,[object Object],[object Object],[object Object],[object Object]
Antihypertensive Drug Classes ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Antihypertensive Agents ,[object Object],[object Object],[object Object],[object Object]
Antihypertensive Agents ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Antihypertensive Agents ,[object Object],[object Object],[object Object],[object Object],[object Object]
Antihypertensive Agents ,[object Object],[object Object],[object Object],[object Object],[object Object]
Antihypertensive Agents ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object]
Learning Objectives ,[object Object],[object Object],[object Object],[object Object],[object Object]
Coagulant Agents ,[object Object],[object Object],[object Object],[object Object]
Coagulant Agents ,[object Object],[object Object],[object Object],[object Object],[object Object]
Anticoagulant Agents ,[object Object],[object Object],[object Object]
Heparin ,[object Object],[object Object],[object Object],[object Object]
Heparin ,[object Object],[object Object],[object Object]
Low–Molecular-Weight Heparin Agents ,[object Object],[object Object],[object Object],[object Object]
Low–Molecular-Weight Heparin Agents ,[object Object],[object Object],[object Object],[object Object]
Direct Inhibitors of Thrombin ,[object Object],[object Object],[object Object],[object Object]
Coumarin Anticoagulant Agents ,[object Object],[object Object],[object Object],[object Object]
Coumarin Anticoagulant Agents ,[object Object],[object Object],[object Object],[object Object]
Thrombolytic Therapy for Myocardial Infarction ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object]
Learning Objectives ,[object Object],[object Object],[object Object]
Antiplatelet Therapy in Cardiovascular Disease  ,[object Object],[object Object],[object Object],[object Object],[object Object]
Antiplatelet Therapy in Cardiovascular Disease ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Antilipidemic Drugs  ,[object Object],[object Object],[object Object],[object Object]
Antilipidemic Drugs ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Antilipidemic Drugs ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Weitere ähnliche Inhalte

Was ist angesagt?

Cardiac Medications #4 08
Cardiac Medications #4 08Cardiac Medications #4 08
Cardiac Medications #4 08gerlam
 
anti hypertensive drugs for nursing students
anti hypertensive drugs for nursing studentsanti hypertensive drugs for nursing students
anti hypertensive drugs for nursing studentsPatel Dharmendra
 
Cardiovascular assessment and diagnostic procedures
Cardiovascular assessment and diagnostic proceduresCardiovascular assessment and diagnostic procedures
Cardiovascular assessment and diagnostic proceduresANILKUMAR BR
 
Hd for residents (2) copy
Hd for residents (2)   copyHd for residents (2)   copy
Hd for residents (2) copyFarragBahbah
 
5-day nutritive cleanse -- YL
5-day nutritive cleanse -- YL5-day nutritive cleanse -- YL
5-day nutritive cleanse -- YLNicole Hayes
 
Rapid clinical interpretation of ABG
Rapid clinical interpretation of ABGRapid clinical interpretation of ABG
Rapid clinical interpretation of ABGMahesh Sivaji
 
Management of Ischemic heart diseases
Management of Ischemic heart diseasesManagement of Ischemic heart diseases
Management of Ischemic heart diseasesSameh Abdel-ghany
 
Chronic kidney disease and its management
Chronic kidney disease and its managementChronic kidney disease and its management
Chronic kidney disease and its managementRajee Ravindran
 
Types of cardiac surgeries
Types of cardiac surgeriesTypes of cardiac surgeries
Types of cardiac surgeriesjagan _jaggi
 
Fluid and electrolyte balance powepoint
Fluid and electrolyte balance powepointFluid and electrolyte balance powepoint
Fluid and electrolyte balance powepointMarjo Malabanan
 
Dialysis prescription 2
Dialysis prescription 2Dialysis prescription 2
Dialysis prescription 2Chioma Iheme
 
Crrt indications and modalities [autosaved]
Crrt indications and modalities [autosaved]Crrt indications and modalities [autosaved]
Crrt indications and modalities [autosaved]FAARRAG
 
Peritoneal Dialysis
Peritoneal Dialysis Peritoneal Dialysis
Peritoneal Dialysis amit jha
 
Hemodialysis complications
Hemodialysis complications Hemodialysis complications
Hemodialysis complications FarragBahbah
 

Was ist angesagt? (20)

Cardiac Medications #4 08
Cardiac Medications #4 08Cardiac Medications #4 08
Cardiac Medications #4 08
 
anti hypertensive drugs for nursing students
anti hypertensive drugs for nursing studentsanti hypertensive drugs for nursing students
anti hypertensive drugs for nursing students
 
Cardiovascular assessment and diagnostic procedures
Cardiovascular assessment and diagnostic proceduresCardiovascular assessment and diagnostic procedures
Cardiovascular assessment and diagnostic procedures
 
Hd for residents (2) copy
Hd for residents (2)   copyHd for residents (2)   copy
Hd for residents (2) copy
 
CONTROVERSIES FOR ASIAN PATIENTS
CONTROVERSIES FOR ASIAN PATIENTSCONTROVERSIES FOR ASIAN PATIENTS
CONTROVERSIES FOR ASIAN PATIENTS
 
5-day nutritive cleanse -- YL
5-day nutritive cleanse -- YL5-day nutritive cleanse -- YL
5-day nutritive cleanse -- YL
 
Nitrates
NitratesNitrates
Nitrates
 
Oxygenation_MAN Lecture
Oxygenation_MAN LectureOxygenation_MAN Lecture
Oxygenation_MAN Lecture
 
Rapid clinical interpretation of ABG
Rapid clinical interpretation of ABGRapid clinical interpretation of ABG
Rapid clinical interpretation of ABG
 
Management of Ischemic heart diseases
Management of Ischemic heart diseasesManagement of Ischemic heart diseases
Management of Ischemic heart diseases
 
Chronic kidney disease and its management
Chronic kidney disease and its managementChronic kidney disease and its management
Chronic kidney disease and its management
 
Chronic Renal Failure
Chronic Renal Failure Chronic Renal Failure
Chronic Renal Failure
 
Types of cardiac surgeries
Types of cardiac surgeriesTypes of cardiac surgeries
Types of cardiac surgeries
 
Fluid and electrolyte balance powepoint
Fluid and electrolyte balance powepointFluid and electrolyte balance powepoint
Fluid and electrolyte balance powepoint
 
Dialysis prescription 2
Dialysis prescription 2Dialysis prescription 2
Dialysis prescription 2
 
11 Peritoneal Dialysis
11 Peritoneal Dialysis11 Peritoneal Dialysis
11 Peritoneal Dialysis
 
Antiplatelet drugs (antithrombotics)
Antiplatelet drugs (antithrombotics)Antiplatelet drugs (antithrombotics)
Antiplatelet drugs (antithrombotics)
 
Crrt indications and modalities [autosaved]
Crrt indications and modalities [autosaved]Crrt indications and modalities [autosaved]
Crrt indications and modalities [autosaved]
 
Peritoneal Dialysis
Peritoneal Dialysis Peritoneal Dialysis
Peritoneal Dialysis
 
Hemodialysis complications
Hemodialysis complications Hemodialysis complications
Hemodialysis complications
 

Andere mochten auch

Andere mochten auch (8)

Pharmacology Git Drugs
Pharmacology   Git DrugsPharmacology   Git Drugs
Pharmacology Git Drugs
 
Vasodilators
VasodilatorsVasodilators
Vasodilators
 
Vasodilators
VasodilatorsVasodilators
Vasodilators
 
Drugs acting on the cns
Drugs acting on the cnsDrugs acting on the cns
Drugs acting on the cns
 
Drugs that act on CNS
Drugs that act on CNSDrugs that act on CNS
Drugs that act on CNS
 
Pharmacology powerpoint git drugs
Pharmacology powerpoint  git drugsPharmacology powerpoint  git drugs
Pharmacology powerpoint git drugs
 
Drugs acting on the gastrointestinal tract
Drugs acting on the gastrointestinal tractDrugs acting on the gastrointestinal tract
Drugs acting on the gastrointestinal tract
 
L1: Drugs acting on the ANS
L1: Drugs acting on the ANSL1: Drugs acting on the ANS
L1: Drugs acting on the ANS
 

Ähnlich wie Drugs affecting the circulatory system

Common Medications
Common MedicationsCommon Medications
Common Medicationsmrevader
 
Cardio Vascular Drugs
Cardio Vascular Drugs Cardio Vascular Drugs
Cardio Vascular Drugs RimshaShafeeq1
 
1. Anti hypertensive drugs.pptx what's hypertension
1. Anti hypertensive drugs.pptx what's hypertension1. Anti hypertensive drugs.pptx what's hypertension
1. Anti hypertensive drugs.pptx what's hypertensionKhyber medical university
 
Atherosclerosis2-Risk factors,Microorganisms,Medications,Classification,Surgi...
Atherosclerosis2-Risk factors,Microorganisms,Medications,Classification,Surgi...Atherosclerosis2-Risk factors,Microorganisms,Medications,Classification,Surgi...
Atherosclerosis2-Risk factors,Microorganisms,Medications,Classification,Surgi...varinder kumar
 
Cardiac medications nursing review 2011
Cardiac medications nursing review 2011Cardiac medications nursing review 2011
Cardiac medications nursing review 2011MicheleMSNCCRN
 
Cardiac Medications Review 2011
Cardiac Medications Review 2011Cardiac Medications Review 2011
Cardiac Medications Review 2011MicheleMSNCCRN
 
CARDIOVASCULAR PHARMACOLOGY.ppt
CARDIOVASCULAR PHARMACOLOGY.pptCARDIOVASCULAR PHARMACOLOGY.ppt
CARDIOVASCULAR PHARMACOLOGY.pptMulatuAsfaw
 
Antihypertensive drugs
Antihypertensive drugsAntihypertensive drugs
Antihypertensive drugsBONI RAFI
 
Antihypertensive drugs.pdf
Antihypertensive drugs.pdfAntihypertensive drugs.pdf
Antihypertensive drugs.pdfAxmedXBullaale
 
Antihypertensive mbbs copy
Antihypertensive mbbs   copyAntihypertensive mbbs   copy
Antihypertensive mbbs copyDivya Krishnan
 
Beta blockers and calcium channel blockers
Beta blockers and calcium channel blockersBeta blockers and calcium channel blockers
Beta blockers and calcium channel blockersUma Binoy
 
Diploma 2nd yr PHARMACOLOGY chapter 5 part 1.pdf
Diploma 2nd yr PHARMACOLOGY chapter 5 part 1.pdfDiploma 2nd yr PHARMACOLOGY chapter 5 part 1.pdf
Diploma 2nd yr PHARMACOLOGY chapter 5 part 1.pdfSumit Tiwari
 
NurseReview.Org - Antihypertensives Updates (pharmacology review notes)
NurseReview.Org - Antihypertensives Updates (pharmacology review notes)NurseReview.Org - Antihypertensives Updates (pharmacology review notes)
NurseReview.Org - Antihypertensives Updates (pharmacology review notes)jben501
 
Antihypertensives
AntihypertensivesAntihypertensives
Antihypertensivesraj kumar
 
ANTI HYPERTENSIVE DRUG
ANTI HYPERTENSIVE DRUGANTI HYPERTENSIVE DRUG
ANTI HYPERTENSIVE DRUGAkshit Naveria
 
Adrenergic-Blocking Drugs
Adrenergic-Blocking DrugsAdrenergic-Blocking Drugs
Adrenergic-Blocking Drugsshabeel pn
 

Ähnlich wie Drugs affecting the circulatory system (20)

Common Medications
Common MedicationsCommon Medications
Common Medications
 
Cardio Vascular Drugs
Cardio Vascular Drugs Cardio Vascular Drugs
Cardio Vascular Drugs
 
1. Anti hypertensive drugs.pptx what's hypertension
1. Anti hypertensive drugs.pptx what's hypertension1. Anti hypertensive drugs.pptx what's hypertension
1. Anti hypertensive drugs.pptx what's hypertension
 
Atherosclerosis2-Risk factors,Microorganisms,Medications,Classification,Surgi...
Atherosclerosis2-Risk factors,Microorganisms,Medications,Classification,Surgi...Atherosclerosis2-Risk factors,Microorganisms,Medications,Classification,Surgi...
Atherosclerosis2-Risk factors,Microorganisms,Medications,Classification,Surgi...
 
Cardiac medications nursing review 2011
Cardiac medications nursing review 2011Cardiac medications nursing review 2011
Cardiac medications nursing review 2011
 
Cardiac Medications Review 2011
Cardiac Medications Review 2011Cardiac Medications Review 2011
Cardiac Medications Review 2011
 
CARDIOVASCULAR PHARMACOLOGY.ppt
CARDIOVASCULAR PHARMACOLOGY.pptCARDIOVASCULAR PHARMACOLOGY.ppt
CARDIOVASCULAR PHARMACOLOGY.ppt
 
Antihypertensive drugs
Antihypertensive drugsAntihypertensive drugs
Antihypertensive drugs
 
Antihypertensive drugs.pdf
Antihypertensive drugs.pdfAntihypertensive drugs.pdf
Antihypertensive drugs.pdf
 
Antihypertensive mbbs copy
Antihypertensive mbbs   copyAntihypertensive mbbs   copy
Antihypertensive mbbs copy
 
Beta blockers and calcium channel blockers
Beta blockers and calcium channel blockersBeta blockers and calcium channel blockers
Beta blockers and calcium channel blockers
 
Diploma 2nd yr PHARMACOLOGY chapter 5 part 1.pdf
Diploma 2nd yr PHARMACOLOGY chapter 5 part 1.pdfDiploma 2nd yr PHARMACOLOGY chapter 5 part 1.pdf
Diploma 2nd yr PHARMACOLOGY chapter 5 part 1.pdf
 
Antianginal Drugs.pdf
Antianginal Drugs.pdfAntianginal Drugs.pdf
Antianginal Drugs.pdf
 
NurseReview.Org - Antihypertensives Updates (pharmacology review notes)
NurseReview.Org - Antihypertensives Updates (pharmacology review notes)NurseReview.Org - Antihypertensives Updates (pharmacology review notes)
NurseReview.Org - Antihypertensives Updates (pharmacology review notes)
 
Antihypertensives
AntihypertensivesAntihypertensives
Antihypertensives
 
ANTI HYPERTENSIVE DRUG
ANTI HYPERTENSIVE DRUGANTI HYPERTENSIVE DRUG
ANTI HYPERTENSIVE DRUG
 
Adrenergic-Blocking Drugs
Adrenergic-Blocking DrugsAdrenergic-Blocking Drugs
Adrenergic-Blocking Drugs
 
Hypertension.pptx
Hypertension.pptxHypertension.pptx
Hypertension.pptx
 
Week 5 Pharma
Week 5 PharmaWeek 5 Pharma
Week 5 Pharma
 
Ant ihypertensive
Ant ihypertensiveAnt ihypertensive
Ant ihypertensive
 

Mehr von sharon49

Artifacts for ne ts1b
Artifacts for ne ts1bArtifacts for ne ts1b
Artifacts for ne ts1bsharon49
 
Angioplasty
AngioplastyAngioplasty
Angioplastysharon49
 
The heart and heart disease
The heart and heart diseaseThe heart and heart disease
The heart and heart diseasesharon49
 
Digital age march 18
Digital age march 18Digital age march 18
Digital age march 18sharon49
 
Power point tutorial
Power point tutorialPower point tutorial
Power point tutorialsharon49
 

Mehr von sharon49 (6)

Artifacts for ne ts1b
Artifacts for ne ts1bArtifacts for ne ts1b
Artifacts for ne ts1b
 
Angioplasty
AngioplastyAngioplasty
Angioplasty
 
Flow
FlowFlow
Flow
 
The heart and heart disease
The heart and heart diseaseThe heart and heart disease
The heart and heart disease
 
Digital age march 18
Digital age march 18Digital age march 18
Digital age march 18
 
Power point tutorial
Power point tutorialPower point tutorial
Power point tutorial
 

Kürzlich hochgeladen

Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfAdmir Softic
 
How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17Celine George
 
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptxSKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptxAmanpreet Kaur
 
How to setup Pycharm environment for Odoo 17.pptx
How to setup Pycharm environment for Odoo 17.pptxHow to setup Pycharm environment for Odoo 17.pptx
How to setup Pycharm environment for Odoo 17.pptxCeline George
 
Kodo Millet PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
Kodo Millet  PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...Kodo Millet  PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
Kodo Millet PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...pradhanghanshyam7136
 
ICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptxICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptxAreebaZafar22
 
Google Gemini An AI Revolution in Education.pptx
Google Gemini An AI Revolution in Education.pptxGoogle Gemini An AI Revolution in Education.pptx
Google Gemini An AI Revolution in Education.pptxDr. Sarita Anand
 
The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxheathfieldcps1
 
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxBasic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxDenish Jangid
 
Sociology 101 Demonstration of Learning Exhibit
Sociology 101 Demonstration of Learning ExhibitSociology 101 Demonstration of Learning Exhibit
Sociology 101 Demonstration of Learning Exhibitjbellavia9
 
Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)Jisc
 
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...Pooja Bhuva
 
On National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan FellowsOn National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan FellowsMebane Rash
 
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...Nguyen Thanh Tu Collection
 
Towards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptxTowards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptxJisc
 
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdf
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdfUnit 3 Emotional Intelligence and Spiritual Intelligence.pdf
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdfDr Vijay Vishwakarma
 
Wellbeing inclusion and digital dystopias.pptx
Wellbeing inclusion and digital dystopias.pptxWellbeing inclusion and digital dystopias.pptx
Wellbeing inclusion and digital dystopias.pptxJisc
 
UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdf
UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdfUGC NET Paper 1 Mathematical Reasoning & Aptitude.pdf
UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdfNirmal Dwivedi
 

Kürzlich hochgeladen (20)

Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdf
 
How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17
 
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptxSKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
 
How to setup Pycharm environment for Odoo 17.pptx
How to setup Pycharm environment for Odoo 17.pptxHow to setup Pycharm environment for Odoo 17.pptx
How to setup Pycharm environment for Odoo 17.pptx
 
Kodo Millet PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
Kodo Millet  PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...Kodo Millet  PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
Kodo Millet PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
 
ICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptxICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptx
 
Google Gemini An AI Revolution in Education.pptx
Google Gemini An AI Revolution in Education.pptxGoogle Gemini An AI Revolution in Education.pptx
Google Gemini An AI Revolution in Education.pptx
 
The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptx
 
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxBasic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
 
Sociology 101 Demonstration of Learning Exhibit
Sociology 101 Demonstration of Learning ExhibitSociology 101 Demonstration of Learning Exhibit
Sociology 101 Demonstration of Learning Exhibit
 
Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)
 
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
 
On National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan FellowsOn National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan Fellows
 
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
 
Towards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptxTowards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptx
 
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdf
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdfUnit 3 Emotional Intelligence and Spiritual Intelligence.pdf
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdf
 
Wellbeing inclusion and digital dystopias.pptx
Wellbeing inclusion and digital dystopias.pptxWellbeing inclusion and digital dystopias.pptx
Wellbeing inclusion and digital dystopias.pptx
 
Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024
 
UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdf
UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdfUGC NET Paper 1 Mathematical Reasoning & Aptitude.pdf
UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdf
 
Spatium Project Simulation student brief
Spatium Project Simulation student briefSpatium Project Simulation student brief
Spatium Project Simulation student brief
 

Drugs affecting the circulatory system

  • 1. Drugs That Affect the Circulatory System
  • 2.
  • 3.
  • 4.
  • 5. Components and Function of the Circulatory System
  • 6.
  • 7.
  • 8.
  • 9.
  • 10.
  • 11.
  • 12.
  • 13.
  • 14.
  • 15.
  • 16.
  • 17.
  • 18.
  • 19.
  • 20.
  • 21.
  • 22.
  • 23.
  • 24.
  • 25.
  • 26.
  • 27.
  • 28.
  • 29.
  • 30.
  • 31.
  • 32.
  • 33.
  • 34.
  • 35.
  • 36.
  • 37.
  • 38.
  • 39.
  • 40.
  • 41.
  • 42.
  • 43.
  • 44.
  • 45.
  • 46.
  • 47.
  • 48.
  • 49.
  • 50.
  • 51.
  • 52.
  • 53.
  • 54.
  • 55.

Hinweis der Redaktion

  1. The heart is divided by partitions into four chambers. What are they? (Answer: right and left atria, and right and left ventricles)
  2. Review the remainder of blood circulation. Venous capillaries merge to form larger veins. Blood returns to the heart via vena cava; enters the right atrium. Right atrium contracts; forces blood into right ventricle. Right ventricle contracts, forces blood to lungs. Blood is oxygenated and returned again to left atrium. What are differences between arteries and veins?
  3. Review the exception: The pulmonary artery carries unoxygenated blood. Review the exception: The pulmonary vein carries oxygenated blood. Discuss the components of the heart that are affected by cardiac medications. Consider muscle contraction, chamber filling, electrical conduction, and rhythm.
  4. Why do these conditions require medication? Explain the effect position and rate of flow of blood has on the client with heart failure.
  5. What types of patients are vulnerable to heart failure?
  6. Review the rationale for various drug classes that affect the heart.
  7. Weight should be obtained daily, early in morning before eating or drinking; the bladder should be empty.
  8. An inotropic drug such as digoxin may be combined with an ACE inhibitor, a beta-blocking agent, and/or a diuretic.
  9. When would a prescription for digoxin immune Fab be used? With digitalis therapy, the rate of heart contraction is slowed. Normal heart rate is 60 to 80 beats per minute.
  10. These medications assist in the treatment of hypertension by suppressing the formation of angiotensin II. The first dose may induce a severe hypotensive reaction. The patient should be closely monitored. The physician may discontinue diuretic agents 2 to 3 days before beginning ACE inhibitor therapy.
  11. ACE inhibitors are excreted through the kidney. These medications may cause a severe decrease in blood pressure and an increase in serum potassium level. These medications should be used with caution for patients with renal compromise or pregnancy-induced hypertension.
  12. Beta-blocking agents can be used alone or in combination with other agents to treat hypertension.
  13. A low incidence of side effects exists with angiotensin II receptor–blocking agents. What are some side effects? (Answer: skin rash, facial edema, insomnia, and myalgia)
  14. These medications are also useful in treating diabetic nephropathy and are usually well tolerated. Valsartan (Diovan) is the only one of the listed medications approved to treat heart failure. The remainder are used to treat hypertension and diabetic nephropathy. If the patient is receiving other drugs for hypertension or heart failure, the physician may decrease the dose or eliminate those drugs.
  15. Aldosterone inhibitor agents include spironolactone, a potassium-sparing diuretic agent. Aldosterone inhibitor agents should not be used for patients with elevated serum potassium levels or decreased renal function. Aldosterone is suspected of causing myocardial remodeling after myocardial infarction. This limits the efficient function of the heart. By inhibiting aldosterone, the heart responds more efficiently and the risk for heart failure is decreased.
  16. Discuss normal sinus rhythm and its rate. Rate for bradycardia: <60 Rate for tachycardia: >100
  17. What disorders or conditions require the use of vasoconstricting agents? (Answer: shock, rhinorrhea, allergic reaction)
  18. Epinephrine is available as an EpiPen.
  19. Vasodilating agents are common medication for home management of angina. Vasodilating agents are often first-line treatment for chest pain in the emergency department. What are the routes of administration? (Answer: sublingual, sustained-release oral tablets and capsules, transdermal, spray, intravenous)
  20. Some medications target the dilation of arteries, increasing cardiac output and tissue perfusion. Some medications target the dilation of veins, easing the work of the ventricles. Some medications target both. Common side effects include postural hypotension, reflex tachycardia, and fluid retention. Nearly one third of patients do not take antihypertensive agents properly.
  21. Most patients have “essential” hypertension (no cause is identified). Other lifestyle issues include the following: obesity, diabetes, arthritis (may affect likelihood of exercise), time constraints Review with students the current American Heart Association blood pressure guidelines (available on the organization’s website). If diet and exercise are not effective, single-drug therapy is begun. If this is not effective, combination therapy is begun with several drugs.
  22. Through vessel dilation, these medications reduce the blood flow and workload of the vessels and the heart. Why is orthostatic hypotension a common side effect for this class of drugs?
  23. Clonidine also may be used to control impulsivity in the hyperactive child or the child with attention deficit disorder. It does not increase school performance. Side effects of Aldomet are drowsiness, impotence, and gynecomastia.
  24. Alpha-blocking agents include prazosin hydrochloride (Minipress), terazosin hydrochloride (Hytrin), and doxazosin mesylate (Cardura). Alpha-blocking agents are also used to treat benign prostatic hypertrophy (BPH) or hyperplasia.
  25. These medications affect peripheral arterioles, arteries and arterioles of the heart, and cardiac muscle. They have no effect on the veins. These medications also affect the sites of the electrical conduction of the heart: the SA and AV nodes.
  26. These medications must be used carefully with digoxin. How does the action of beta-blocking agents differ from calcium channel–blocking agents? Common side effects include bradycardia, AV block, exacerbation of heart failure, reflex tachycardia, dizziness, and peripheral edema.
  27. Calcium salts include calcium gluconate, calcium chloride, and calcium lactate.
  28. Drugs include the following: Phytonadione (vitamin K 1 oxide), (Mephyton) Phytonadione injection (AquaMEPHYTON) Administered by the oral or intravenous route. Intravenous administration may cause a severe adverse reaction. Vitamin K injection is administered at birth because infants are bone deficient in vitamin K and are at risk for neonatal hemorrhage.
  29. Prothrombin time (PT) is used to evaluate the effectiveness of warfarin and guard against overdose. International normalized ratio (INR) is a system of standardizing the PT values. What is meant when patients say they take a “blood thinner”? How does an anticoagulant agent “thin” the blood?
  30. Subcutaneous administration is seldom used because of the risk for bruising and bleeding. Heparin is used for prevention and treatment of pulmonary embolism, arterial emboli, and treatment of consumption coagulopathies (like disseminated intravascular coagulation [DIC]). Heparin encourages the antithrombin activity by altering the thrombin part of the clotting cascade.
  31. The lab value activated partial thromboplastin time (aPTT) is used to monitor response to therapy and coagulation. Normal aPTT is approximately 40 seconds. Treatment range for aPTT is usually between 60 and 80 seconds (depends on the patient situation). Review the patient situations that would require heparin treatment. What are the signs and symptoms of the side effects of heparin?
  32. Advantages over unfractionated heparin agents: May be given by subcutaneous injection Have a longer half-life, and thus may be administered less frequently Lower incidence of antiplatelet formation and HIT May be given on a fixed schedule. No need to monitor aPTT because of the low molecular weight. Low–molecular-weight heparin is more expensive than heparin, but many patients can remain at home and self-administer this treatment.
  33. The dose is based on body weight. This medication may be given as prophylaxis to prevent deep vein thrombosis. It may be used to treat an active deep vein thrombosis. Review with students the patient teaching regarding subcutaneous administration, home care, and use of this medication.
  34. Lepirudin directly inhibits thrombin formation. It is used to reverse HIT while maintaining the anticoagulation in the patient. Common side effects include back pain, nausea, hypotension, and hemorrhage.
  35. Heparin must be given for initial treatment while coumarin is being started. Neither large loading doses nor administration using the intramuscular or intravenous route hastens antithrombotic action.
  36. Dose may be adjusted by using the PT or INR.
  37. This therapy is used for acute myocardial infarction, deep vein thrombosis, and massive pulmonary emboli. For myocardial infarction treatment, therapy must be administered within 4 to 6 hours of symptom presentation. Common side effects include hemorrhage, antibody production, fever, and hypotension.
  38. These medications prevent thrombus formation in the arteries. An anticoagulant agent is used to prevent thrombus formation in the veins. They are useful for the prevention of a myocardial infarction (either initial or recurring). They are useful for decreasing the risk for stroke for patients with history of transient ischemic attacks (TIAs).
  39. These medications increase the risk of gastrointestinal bleeding and also increase the risk of hemorrhage and hemorrhagic stroke.
  40. Present guidelines recommend obtaining a complete lipoprotein and triglyceride profile every 5 years beginning at age 20. A low blood cholesterol level is unattainable for many patients using diet alone. Atherosclerosis is the fatty streak in the arterial wall. Atherosclerosis encourages fibrin formation and subsequent thrombi.
  41. Many lipid-lowering drugs must be taken later in the day, with the evening meal. Some drugs decrease production of cholesterol. Others increase the removal of cholesterol from the bloodstream.
  42. Lab testing of lipid levels and liver enzymes is necessary.